ANP32E
Acidic leucine-rich nuclear phosphoprotein 32 family member E
Protein Summary
Histone chaperone that specifically mediates the genome-wide removal of histone H2A.Z/H2AFZ from the nucleosome: removes H2A.Z/H2AFZ from its normal sites of deposition, especially from enhancer and insulator regions. Not involved in deposition of H2A.Z/H2AFZ in the nucleosome. May stabilize the evicted H2A.Z/H2AFZ-H2B dimer, thus shifting the equilibrium towards dissociation and the off-chromatin state (PubMed:24463511). Inhibits activity of protein phosphatase 2A (PP2A). Does not inhibit protein phosphatase 1. May play a role in cerebellar development and synaptogenesis.
- ENST00000436748
- ENSP00000393718
- ENSG00000143401
- ENST00000583931
- ENSP00000463154
- ENST00000616917
- ENSP00000481415
- LANPL
- LANP-L
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
transcription factor perturbation | 0.94 | ||
transcription factor binding site profile | 0.92 | ||
small molecule perturbation | 0.9 | ||
cellular component | 0.75 | ||
microRNA | 0.74 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 18.9 (req: < 5)
Gene RIFs: 14 (req: <= 3)
Antibodies: 120 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 18.9 (req: >= 5)
Gene RIFs: 14 (req: > 3)
Antibodies: 120 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 3
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0